DCGI Approves Anti-COVID Drug Developed by DRDO for Emergency Use, How Will it Work?
A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients and will be of immense benefit to the people suffering from COVID-19.
| 10 May 2021 7:14 AM GMT
NEW DELHI: An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.
Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.